Edgewise Therapeutics (EWTX) Total Liabilities (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Total Liabilities data on file, last reported at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 2.62% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.3 million (up 2.62% YoY), and the FY2025 full-year result was $30.3 million, up 9.95% from the prior year.
• Total Liabilities fell to $25.3 million in Q1 2026, from $30.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $30.3 million in Q4 2025 to a low of $11.0 million in Q2 2022.
• A 5-year average of $21.1 million and a median of $21.2 million in 2024 frame the typical range for Total Liabilities.
• Peak annual rise in Total Liabilities reached 87.88% in 2022, while the deepest fall reached 96.36% in 2022.
• Tracing EWTX's Total Liabilities over 5 years: stood at $20.4 million in 2022, then grew by 4.02% to $21.2 million in 2023, then jumped by 30.16% to $27.6 million in 2024, then gained by 9.95% to $30.3 million in 2025, then declined by 16.57% to $25.3 million in 2026.
• Business Quant data shows EWTX's Total Liabilities at $25.3 million in Q1 2026, $30.3 million in Q4 2025, and $24.8 million in Q3 2025.